-+ 0.00%
-+ 0.00%
-+ 0.00%

Recently, an investor asked Haichen Pharmaceutical on an interactive platform: Does the company have a first-class new drug layout? How is it progressing so far? On November 17, Haichen Pharmaceutical replied that the company is currently developing mainly generic drugs with high added value. At the same time, it has also laid out a class of new drugs, and related projects are still in the early stages of development. New drug development has the characteristics of long cycle, large investment, and high risk, and there is uncertainty about the progress and results of subsequent research and development. Haichen Pharmaceutical's main business is R&D, production and sales of chemical preparations, APIs and intermediates. Among them, the parent company Nanjing Haichen Pharmaceutical and the wholly-owned subsidiary Zhenjiang Derui are mainly engaged in R&D, production and sales of chemical preparations, APIs and intermediates.

Zhitongcaijing·11/17/2026 11:57:11
Listen to the news
Recently, an investor asked Haichen Pharmaceutical on an interactive platform: Does the company have a first-class new drug layout? How is it progressing so far? On November 17, Haichen Pharmaceutical replied that the company is currently developing mainly generic drugs with high added value. At the same time, it has also laid out a class of new drugs, and related projects are still in the early stages of development. New drug development has the characteristics of long cycle, large investment, and high risk, and there is uncertainty about the progress and results of subsequent research and development. Haichen Pharmaceutical's main business is R&D, production and sales of chemical preparations, APIs and intermediates. Among them, the parent company Nanjing Haichen Pharmaceutical and the wholly-owned subsidiary Zhenjiang Derui are mainly engaged in R&D, production and sales of chemical preparations, APIs and intermediates.